Article information
Abstract
Tuberculosis is an opportunistic infection with high morbidity and mortality in solid organ transplant patients. The reasons for this high morbidity and mortality lie mostly in diagnostic difficulties, which cause delays in starting treatment, and associated pharmaceutical toxicity. There are still major issues and difficulties in managing tuberculosis in solid organ transplant patients. These include problems due to interactions between antituberculosis and immunosuppressant drugs, the high risk of toxicity of antituberculosis drugs (particularly in liver transplant patients) and the absence of clear indications for the treatment of latent tuberculous infection. This article updates current understanding of tuberculosis in solid organ transplant patients.
Keywords:
Latent tuberculous infection
Mycobacterium tuberculosis
Solid organ transplantation
Tuberculosis
Resumen
La tuberculosis es una infección oportunista con una elevada morbimortalidad en los pacientes trasplantados de órgano sólido. Esta elevada morbimortalidad radica, sobre todo, en las dificultades en el diagnóstico, que condicionan un retraso en el inicio del tratamiento, así como en la toxicidad farmacológica asociada. En la actualidad continúan existiendo importantes dudas y dificultades en el manejo de la tuberculosis en los pacientes trasplantados de órgano sólido, como son las que se deben a las interacciones existentes entre fármacos antituberculosos e inmunosupresores, al elevado riesgo de toxicidad de los fármacos antituberculosos, particularmente en los trasplantados hepáticos o a la ausencia de indicaciones claras sobre el tratamiento de la infección tuberculosa latente. En este artículo se actualiza el estado del conocimiento sobre la tuberculosis en los pacientes trasplantados de órgano sólido.
Palabras clave:
Infección tuberculosa latente
Mycobacterium tuberculosis
Trasplante de órgano sólido
Tuberculosis
Full text is only aviable in PDF
References
[1.]
J. Torre-Cisneros, A. Doblas, J.M. Aguado, R. San Juan, M. Blanes, M. Montejo, et al.
Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort.
Clin Infect Dis, 48 (2009), pp. 1657-1665
[2.]
N. Singh, D.L. Paterson.
Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management.
Clin Infect Dis, 27 (1998), pp. 1266-1277
[3.]
J.M. Aguado, J.A. Herrero, J. Gavaldà, J. Torre-Cisneros, M. Blanes, G. Rufi, et al.
Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA.
Transplantation, 63 (1997), pp. 1278-1286
[4.]
P. Muñoz, C. Rodríguez, E. Bouza.
Mycobacterium tuberculosis infection in recipients of solid organ transplants.
Clin Infect Dis, 40 (2005), pp. 581-587
[5.]
P. Morales, A. Briones, J.J. Torres, A. Solé, D. Pérez, A. Pastor.
Pulmonary tuberculosis in lung and heart-lung transplantation: fifteen years of experience in a single center in Spain.
Transplant Proc, 37 (2005), pp. 4050-4055
[6.]
R.M. Muñoz, L.A. Pulpón, M. Yebra, J. Segovia, M. San Martín, C. Salas.
Three cases of tuberculosis after heart transplantation in Spain.
Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 801-806
[7.]
M.M. Korner, N. Hirata, G. Tenderich, K. Minami, H. Mannebach, K. Kleesiek, et al.
Tuberculosis in heart transplant recipients.
Chest, 111 (1997), pp. 365-369
[8.]
G.T. John, V. Shankar.
Mycobacterial infections in organ transplant recipients.
Semin Respir Infect, 17 (2002), pp. 274-283
[9.]
A. Basiri, S.M. Moghaddam, N. Simforoosh, B. Einollahi, M. Hosseini, A. Foirouzan, et al.
Preliminary report of a nationwide case-control study for identifying risk factors of tuberculosis following renal transplantation.
Transplant Proc, 37 (2005), pp. 3041-3044
[10.]
A. Basiri, S.M. Hosseini-Moghaddam, N. Simforoosh, B. Einollahi, M. Hosseini, A. Foirouzan, et al.
The risk factors and laboratory diagnostics for post renal transplant tuberculosis: a case-control, country-wide study on definitive cases.
Transpl Infect Dis, 10 (2008), pp. 231-235
[11.]
M.M. Klote, L.Y. Agodoa, K. Abbott.
Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998–2000.
Am J Transplant, 4 (2004), pp. 1523-1528
[12.]
G.T. John, V. Shankar, A.M. Abraham, U. Mukundan, P.P. Thomas, C.K. Jacob.
Risk factors for post-transplant tuberculosis.
Kidney Int, 60 (2001), pp. 1148-1153
[13.]
G.T. John, L. Vincent, L. Jeyaseelan, C.K. Jacob, J.C. Shastry.
Cyclosporine immunosuppression and mycobacterial infections.
Transplantation, 58 (1994), pp. 247-249
[14.]
N. Benito, O. Sued, A. Moreno, J.P. Horcajada, J. González, M. Navasa, et al.
Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area.
Transplantation, 74 (2002), pp. 1381-1386
[15.]
J. Torres, J.M. Aguado, R. San Juan, A. Andrés, P. Sierra, F. López-Medrano, et al.
Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation.
Transpl Int, 21 (2008), pp. 873-878
[16.]
P. Muñoz, J. Palomo, R. Muñoz, M. Rodriguez-Creixems, T. Peláez, E. Bouza.
Tuberculosis in heart transplant recipients.
Clin Infect Dis, 21 (1995), pp. 398-402
[17.]
A. Atasever, F. Bacakoglu, H. Toz, O.K. Basoglu, S. Duman, K. Basak, et al.
Tuberculosis in renal transplant recipients on various immunosuppressive regimens.
Nephrol Dial Transplant, 20 (2005), pp. 797-802
[18.]
G. Rose.
The risk of tuberculosis transmission in solid organ transplantation: Is it more than a theoretical concern?.
Can J Infect Dis Med Microbiol, 16 (2005), pp. 304-308
[19.]
J.C. Graham, A.M. Kearns, J.G. Magee, M.F. El-Sheikh, M. Hudson, D. Manas, et al.
Tuberculosis transmitted through transplantation.
J Infect, 43 (2001), pp. 251-254
[20.]
A. Malone, S. McConkey, A. Dorman, P. Lavin, D. Gopthanian, P. Conlon.
Mycobacterium tuberculosis in a renal transplant transmitted from the donor.
Ir J Med Sci, 176 (2007), pp. 233-235
[21.]
K.L. Winthrop, B.M. Kubak, D.A. Pegues, C. Hufana, P. Costamagna, E. Desmond, et al.
Transmission of mycobacterium tuberculosis via lung transplantation.
Am J Transplant, 4 (2004), pp. 1529-1533
[22.]
Transplantation-transmitted tuberculosis -Oklahoma and Texas, 2007.
MMWR Morb Mortal Wkly Rep, 57 (2008), pp. 333-336
[23.]
A. Verma, A. Dhawan, J.J. Wade, W.H. Lim, G. Ruiz, J.F. Price, et al.
Mycobacterium tuberculosis infection in pediatric liver transplant recipients.
Pediatr Infect Dis J, 19 (2000), pp. 625-630
[24.]
K. Skogberg, P. Ruutu, P. Tukiainen, V. Valtonen.
Effect of immunosuppressive therapy on the clinical presentation and outcome of tuberculosis.
Clin Infect Dis, 17 (1993), pp. 1012-1017
[25.]
J. Torre-Cisneros, M. De la Mata, S. Rufián, J.L. Villanueva Marcos, J. Gutiérrez Aroca, M. Casal, et al.
Importance of surveillance mycobacterial cultures after liver transplantation.
Transplantation, 60 (1995), pp. 1054-1055
[26.]
Guidelines for the Prevention and Management of Infectious Complications of Solid Organ Transplantation.
Mycobacterium tuberculosis.
Am J Transplant, 4 (2004), pp. 37-41
[27.]
J. González-Martín, J.M. García-García, L. Anibarro, R. Vidal, J. Esteban, R. Blanquer, et al.
Consensus document on the diagnosis, treatment and prevention of tuberculosis.
Enferm Infecc Microbiol Clin, 28 (2010), pp. 297e1-3020e
[28.]
Alcaide F, Esteban J, González J, Palacios JJ. Micobacterias. En: Cercenado E, Cantón R, editores. Procedimientos en microbiología clínica. Recomendaciones de la Sociedad de Enfermedades Infecciosas y Microbiología Clínica [9a]. SEIMC, 2005. Available at: http://www.seimc.org/documentos/protocolos/microbiologia/cap9a.pdf
[29.]
R. Moure, L. Muñoz, M. Torres, M. Santín, R. Martín, F. Alcaide.
Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method.
J Clin Microbiol, 49 (2011), pp. 1137-1139
[30.]
C.C. Boehme, M.P. Nicol, P. Nabeta, J.S. Michael, E. Gotuzzo, R. Tahirli, et al.
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.
Lancet, 377 (2011), pp. 1495-1505
[31.]
V. Vadwai, C. Boehme, P. Nabeta, A. Shetty, D. Alland, C. Rodrigues.
Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?.
J Clin Microbiol, 49 (2011), pp. 2540-2545
[32.]
C.C. Boehme, P. Nabeta, D. Hillemann, M.P. Nicol, S. Shenai, F. Krapp, et al.
Rapid molecular detection of tuberculosis and rifampin resistance.
N Engl J Med, 363 (2010), pp. 1005-1015
[33.]
S. Swaminathan, C. Padmapriyadarsini, G. Narendran.
HIV-associated tuberculosis: clinical update.
Clin Infect Dis, 50 (2010), pp. 1377-1386
[34.]
J.A. Queipo, E. Broseta, M. Santos, J. Sánchez-Plumed, A. Budia, F. Jiménez-Cruz.
Mycobacterial infection in a series of 1261 renal transplant recipients.
Clin Microbiol Infect, 9 (2003), pp. 518-525
[35.]
J. Lee, W.W. Yew, C.F. Wong, P.C. Wong, C.S. Chiu.
Multidrug-resistant tuberculosis in a lung transplant recipient.
J Heart Lung Transplant, 22 (2003), pp. 1168-1173
[36.]
G. Di Perri, R. Luzzati, A. Forni, B. Allegranzi, A. Cazzadori, S. Bonora, et al.
Fatal primary multidrug-resistant tuberculosis in a heart transplant recipient.
Transpl Int, 11 (1998), pp. 305-307
[37.]
L. Richeldi.
An update on the diagnosis of tuberculosis infection.
Am J Respir Crit Care Med, 174 (2006), pp. 736-742
[38.]
H.M. Blumberg, M.K. Leonard Jr., R.M. Jasmer.
Update on the treatment of tuberculosis and latent tuberculosis infection.
JAMA, 293 (2005), pp. 2776-2784
[39.]
S.H. Kim, S.O. Lee, J.B. Park, I.A. Park, S.J. Park, S.C. Yun, et al.
A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients.
Am J Transplant, 11 (2011), pp. 1927-1935
[40.]
N. Theodoropoulos, F. Lanternier, J. Rassiwala, G. McNatt, L. Preczewski, E. Demayo, et al.
Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: a single-center retrospective study.
Transpl Infect Dis, 26 (2011),
[41.]
A. Doblas, J. Torre-Cisneros.
The current state of tuberculosis in solid organ transplantation: three principles for optimal management.
Am J Transplant, 11 (2011), pp. 1769-1770
[42.]
M. Arias Guillén, R. Palomar, M. Arias.
Advances in the diagnosis of latent tuberculosis infection in patients receiving renal replacement therapy.
Nefrologia, 31 (2011), pp. 137-141
[43.]
A. Lalvani, M. Pareek.
Interferon gamma release assays: principles and practice.
Enferm Infecc Microbiol Clin, 28 (2010), pp. 245-252
[44.]
S. Casas, L. Muñoz, R. Moure, J. Castellote, M. Guerra, L. González, et al.
Comparison of the 2-step tuberculin skin test and the quantiFERON-TB gold in-tube test for the screening of tuberculosis infection before liver transplantation.
Liver Transpl, 17 (2011), pp. 1205-1211
[45.]
J.M. Aguado, J. Torre-Cisneros, J. Fortún, N. Benito, Y. Meije, A. Doblas, et al.
Consensus document for the management of tuberculosis in solid organ transplant recipients.
Enferm Infecc Microbiol Clin, 27 (2009), pp. 465-473
[46.]
J.M. Aguado, J. Torre-Cisneros, J. Fortún, N. Benito, Y. Meije, A. Doblas, et al.
Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.
Clin Infect Dis, 48 (2009), pp. 1276-1284
[47.]
N. Singh, M.M. Wagener, T. Gayowski.
Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis.
Transplantation, 74 (2002), pp. 892-895
[48.]
A. Sayiner, T. Ece, S. Duman, A. Yildiz, M. Ozkahya, Z. Kilicaslan, et al.
Tuberculosis in renal transplant recipients.
Transplantation, 68 (1999), pp. 1268-1271
[49.]
M.H. Al-Sulaiman, J.M. Dhar, A.A. Al-Khader.
Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine.
Transplantation, 50 (1990), pp. 597-598
[50.]
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 7. 2. Late infections.
Tuberculosis. Nephrol Dial Transplant, 17 (2002), pp. 39-43
[51.]
R.Y. Chenhsu, C.C. Loong, M.H. Chou, M.F. Lin, W.C. Yang.
Renal allograft dysfunction associated with rifampin-tacrolimus interaction.
Ann Pharmacother, 34 (2000), pp. 27-31
[52.]
F.A. Khan, J. Minion, M. Pai, S. Royce, W. Burman, A.D. Harries, et al.
Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.
Clin Infect Dis, 50 (2010), pp. 1288-1299
[53.]
A. López-Montes, E. Gallego, E. López, J. Pérez, I. Lorenzo, F. Llamas, et al.
Treatment of tuberculosis with rifabutin in a renal transplant recipient.
Am J Kidney Dis, 44 (2004), pp. e59-e63
[54.]
Y.S. Park, J.Y. Choi, C.H. Cho, K.H. Chang, Y.G. Song, Y.S. Kim, et al.
Clinical outcomes of tuberculosis in renal transplant recipients.
Yonsei Med J, 45 (2004), pp. 865-872
